🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

82 results for “Karyopharm” Clear

  1. ONDANSETRON ZYDUS 8 mg, comprimé orodispersible, Jakavi 5 mg tablets, EMEND 125 mg+80 mg hard capsules, Jakavi 15 mg tablets, Jakavi 20 mg tablets, PALONOSETRON, NETUPITANT, Akynzeo 300 mg/0.5 mg hard capsules, Selinexor placebo for 20 mg tablets formulated for oral administration., Jakavi 10 mg tablets, SELINEXOR, ONDANSETRON

    Karyopharm Therapeutics

    Treatment naïve patients with MF

    phase 3 small molecule active

    1 trial

  2. Ondansetron Aurobindo 8 mg Filmtabletten, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Zarzio 48 MU/0.5 ml solution for injection or infusion in pre-filled syringe, Rixathon 500 mg concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion, Dexametazona Krka 4 mg comprimate, EMEND 125 mg+80 mg hard capsules, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, G

    Karyopharm Therapeutics

    Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)

    phase 3 small molecule active

    1 trial

  3. SELINEXOR, Selinexor placebo for 20 mg tablets is formulated for oral administration. selinexor placebo tablets are film coated bi-convex round tablets

    Karyopharm Therapeutics

    endometrial cancer

    phase 3 small molecule active

    1 trial

  4. Selinexor

    Karyopharm Therapeutics

    Multiple Myeloma

    phase 3 small molecule active

    12 trials

  5. Selinexor

    Karyopharm Therapeutics

    Myelofibrosis

    phase 3 small molecule active

    2 trials

  6. Selinexor

    Karyopharm Therapeutics

    Dedifferentiated Liposarcoma

    phase 3 small molecule completed

    1 trial

  7. Selinexor

    Karyopharm Therapeutics

    Endometrial Cancer

    phase 3 small molecule active

    2 trials

  8. Selinexor (combination therapy)

    Karyopharm Therapeutics

    Relapsed/Refractory Diffuse Large B-cell Lymphoma

    phase 3 small molecule active

    1 trial

  9. A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

    Karyopharm Therapeutics

    Relapsed/Refractory DLBCL, Relapsed/Refractory DLBCL, Relapsed/Refractory DLBCL

    phase 2 other active

    1 trial

  10. Abemaciclib, dexamethasone, ixazomib, pomalidomide

    Karyopharm Therapeutics

    Relapsed Refractory Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  11. Cyclophosphamide

    Karyopharm Therapeutics

    Myeloma Multiple

    phase 2 small molecule terminated

    1 trial

  12. Decitabine

    Karyopharm Therapeutics

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  13. Docetaxel

    Karyopharm Therapeutics

    Recurrent Squamous Cell Lung Carcinoma

    phase 2 small molecule terminated

    1 trial

  14. Elotuzumab, Selinexor, and Dexamethasone (ESd)

    Karyopharm Therapeutics

    Relapsed Multiple Myeloma

    phase 2 small molecule terminated

    1 trial

  15. Ibrutinib

    Karyopharm Therapeutics

    Lymphoma

    phase 2 small molecule active

    1 trial

  16. KPT-8602

    Karyopharm Therapeutics

    Relapsed/Refractory Multiple Myeloma (RRMM)

    phase 2 small molecule completed

    1 trial

  17. Ondansetron Aurobindo 8 mg Filmtabletten, Dexamethasone 4 mg tablets, ZYPREXA 2.5 mg coated tablets, SELINEXOR, Bortezomib Accord 3.5 mg powder for solution for injection

    Karyopharm Therapeutics

    Penta-refractory multiple myeloma and triple-class refractory multiple myeloma

    phase 2 small molecule active

    1 trial

  18. Open Label Selinexor

    Karyopharm Therapeutics

    Thymoma

    phase 2 small molecule terminated

    1 trial

  19. PALONOSETRON, Jakavi 10 mg tablets, ONDANSETRON, NETUPITANT, APREPITANT, PACRITINIB, Jakavi 5 mg tablets, SELINEXOR

    Karyopharm Therapeutics

    moderate thrombocytopenia, JAK inhibitor-naïve myelofibrosis

    phase 2 small molecule active

    1 trial

  20. Pacritinib

    Karyopharm Therapeutics

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  21. Pembrolizumab

    Karyopharm Therapeutics

    Advanced Urothelial Carcinoma

    phase 2 mab terminated

    1 trial

  22. SELINEXOR

    Karyopharm Therapeutics

    Myelofibrosis

    phase 2 small molecule active

    1 trial

  23. Selinexor

    Karyopharm Therapeutics

    Acute Myeloid Leukemia

    phase 2 small molecule completed

    1 trial

  24. Selinexor

    Karyopharm Therapeutics

    Acute Myeloid Leukemia (Relapsed/Refractory)

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources